RE:Tempest Therap. From $0.23 to $9.77 in 1 dayShares of Tempest Therapeutics Inc. TPST soared nearly 4,000% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.
The drug candidate, in combination with the Roche Holding AG RHHBY treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.
Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said
The results were impressive; the combined effort of TPST-1120, atezolizumab, and bevacizumab produced a 30% ORR rate against just atezolizumab and bevacizumab alone, which could only deliver a 13.3% ORR rate.
https://www.tipranks.com/news/tempest-therapeutics-nasdaqtpst-explodes-upward-on-new-data-release